BAJAJ BROKING

Notification close image
No new Notification messages
card image
Amanta Healthcare Ltd IPO
Apply for the Amanta Healthcare Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

524606

BERLDRG

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

BERYL DRUGS LTD. Share Price Update

As of the latest trading session, BERYL DRUGS LTD. share price is currently at ₹ 25.65, which is down by ₹ -0.85 from its previous closing. Today, the stock has fluctuated between ₹ 25.00 and ₹ 27.49. Over the past year, BERYL DRUGS LTD. has achieved a return of -15.14 %. In the last month alone, the return has been 26.19 %. Read More...

Investment Returns

Over 1 Month 26.19% Over 3 Months 43.24% Over 6 Months 19.15% Over 1 Year -15.14%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

BERYL DRUGS LTD. fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    12.70

  • P/E Ratio (TTM)

    57.61

  • Beta

    0.48

  • Book Value / share

    18.69

  • Return on equity

    9.07%

  • EPS (TTM)

    0.46

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    0.02

info icon alternate text

BERYL DRUGS LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 4.79
Operating Expense 4.77
Net Profit 0.02
Net Profit Margin (%) 0.41
Earnings Per Share (EPS) 0.04
EBITDA 0.55
Effective Tax Rate (%) 71.42
Particulars MAR 2025 (Values in Cr)
Revenue 3.97
Operating Expense 5.12
Net Profit 0.15
Net Profit Margin (%) 3.77
Earnings Per Share (EPS) 0.30
EBITDA 0.50
Effective Tax Rate (%) -50.00
Particulars DEC 2024 (Values in Cr)
Revenue 5.31
Operating Expense 5.24
Net Profit 0.05
Net Profit Margin (%) 0.94
Earnings Per Share (EPS) 0.10
EBITDA 0.59
Effective Tax Rate (%) 68.75
Particulars SEP 2024 (Values in Cr)
Revenue 5.61
Operating Expense 5.53
Net Profit 0.01
Net Profit Margin (%) 0.17
Earnings Per Share (EPS) 0.01
EBITDA 0.56
Effective Tax Rate (%) 90.90
Particulars JUN 2024 (Values in Cr)
Revenue 6.25
Operating Expense 5.79
Net Profit 0.37
Net Profit Margin (%) 5.92
Earnings Per Share (EPS) 0.73
EBITDA 0.99
Effective Tax Rate (%) 26.00
Particulars MAR 2025 (Values in Cr)
Revenue 21.15
Operating Expense 21.69
Net Profit 0.58
Net Profit Margin (%) 2.74
Earnings Per Share (EPS) 1.14
EBITDA 2.65
Effective Tax Rate (%) 33.33
Particulars MAR 2024 (Values in Cr)
Revenue 26.73
Operating Expense 26.11
Net Profit 0.77
Net Profit Margin (%) 2.88
Earnings Per Share (EPS) 1.52
EBITDA 2.67
Effective Tax Rate (%) 23.76
Particulars MAR 2023 (Values in Cr)
Revenue 26.89
Operating Expense 26.18
Net Profit 0.77
Net Profit Margin (%) 2.86
Earnings Per Share (EPS) 1.52
EBITDA 2.21
Effective Tax Rate (%) 22.44
Particulars MAR 2022 (Values in Cr)
Revenue 14.60
Operating Expense 15.71
Net Profit -0.66
Net Profit Margin (%) -4.52
Earnings Per Share (EPS) -1.30
EBITDA 0.58
Effective Tax Rate (%) 30.52
Particulars MAR 2021 (Values in Cr)
Revenue 14.09
Operating Expense 14.39
Net Profit 0.24
Net Profit Margin (%) 1.70
Earnings Per Share (EPS) 0.47
EBITDA 2.09
Effective Tax Rate (%) 31.42
Particulars MAR 2024 (Values in Cr)
Book Value / Share 17.52
ROE % 9.07
ROCE % 11.38
Total Debt to Total Equity 0.57
EBITDA Margin 10.33
Particulars MAR 2023 (Values in Cr)
Book Value / Share 15.84
ROE % 10.03
ROCE % 10.76
Total Debt to Total Equity 0.64
EBITDA Margin 8.44
Particulars MAR 2022 (Values in Cr)
Book Value / Share 14.32
ROE % -8.67
ROCE % -3.56
Total Debt to Total Equity 0.68
EBITDA Margin 4.11
Particulars MAR 2021 (Values in Cr)
Book Value / Share 15.57
ROE % -1.29
ROCE % 2.79
Total Debt to Total Equity 0.67
EBITDA Margin 11.64
Particulars MAR 2020 (Values in Cr)
Book Value / Share 14.97
ROE % 0.66
ROCE % 3.98
Total Debt to Total Equity 0.56
EBITDA Margin 8.89
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.22
Total Assets 17.48
Total Liabilities 17.48
Total Equity 8.92
Share Outstanding 5071700
Price to Book Ratio 1.67
Return on Assets (%) 4.39
Return on Capital (%) 5.48
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.57
Total Assets 17.51
Total Liabilities 17.51
Total Equity 8.06
Share Outstanding 5071700
Price to Book Ratio 0.77
Return on Assets (%) 4.37
Return on Capital (%) 6.08
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.67
Total Assets 17.82
Total Liabilities 17.82
Total Equity 7.29
Share Outstanding 5071700
Price to Book Ratio 0.73
Return on Assets (%) -3.69
Return on Capital (%) -5.24
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.45
Total Assets 18.64
Total Liabilities 18.64
Total Equity 7.92
Share Outstanding 5072000
Price to Book Ratio 0.42
Return on Assets (%) 1.28
Return on Capital (%) 1.84
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.39
Total Assets 16.91
Total Liabilities 16.91
Total Equity 7.62
Share Outstanding 5071700
Price to Book Ratio 0.24
Return on Assets (%) 0.28
Return on Capital (%) 0.39
Particulars MAR 2024 (Values in Cr)
Net Income 1.00
Cash from Operations 1.02
Cash from Investing -1.08
Cash from Financing 0.10
Net change in Cash -0.15
Free Cash Flow 2.37
Particulars MAR 2023 (Values in Cr)
Net Income 0.98
Cash from Operations 2.54
Cash from Investing -1.30
Cash from Financing -1.16
Net change in Cash 0.01
Free Cash Flow 4.10
Particulars MAR 2022 (Values in Cr)
Net Income -0.95
Cash from Operations -0.43
Cash from Investing 0.52
Cash from Financing -0.23
Net change in Cash -0.18
Free Cash Flow -0.02
Particulars MAR 2021 (Values in Cr)
Net Income 0.34
Cash from Operations 0.36
Cash from Investing 0.25
Cash from Financing -0.53
Net change in Cash 0.05
Free Cash Flow 1.41
Particulars MAR 2020 (Values in Cr)
Net Income 0.15
Cash from Operations 0.33
Cash from Investing -1.55
Cash from Financing 1.66
Net change in Cash 0.29
Free Cash Flow 2.20
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 31.16 12.72 1.70 238.79 30.00 / 69.50
BLISS GVS PHARMA LTD 158.10 15.64 1.58 1667.92 105.05 / 190.65
CIPLA LTD 1587.60 23.78 4.11 128239.04 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 322.55 9.08 2.61 949.30 219.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2804.55 50.17 24.34 47510.77 1924.30 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 31.16 16.93 4.92 238.79 30.00 / 69.50
AMRUTAJAN HEALTH LTD 720.55 38.21 6.37 2083.16 548.05 / 838.00
ASTRAZENECA PHARMA IND LT 8751.75 103.46 28.40 21879.38 6222.35 / 10653.05
BLISS GVS PHARMA LTD 158.10 23.63 1.57 1667.92 105.05 / 190.65

BERYL DRUGS LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
25.08 -5.35 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 25.40
  • 26 Days 22.30
  • 10 Days 24.10
  • 50 Days 21.60
  • 12 Days 23.70
  • 100 Days 22.30
  • 20 Days 22.70
  • 200 Days 24.80
26.40 PIVOT

First Support

26.09

First Resistance

26.82

Second Support

25.67

Second Resistance

27.13

Third Support

25.36

Third Resistance

27.55

RSI

66.71

ADX

35.40

MACD

1.38

Williams % R

-30.15

Commodity Channel Index (CCI)

144.71

Date

2025-09-01

Week

7206.00

Same Day

3690.00

Month

3534.00

1 Year

0.48

3 Year

0.41

Over 1 Month

26.19%

down

Over 1 Year

-15.14%

down

Over 3 Months

43.24%

down

Over 3 Years

40.27%

down

Over 6 Months

19.15%

down

Over 5 Years

28.71%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

BERYL DRUGS LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Name Shares Category

News

Left Arrow
Right Arrow

BERYL DRUGS LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

BERYL DRUGS LTD. Share Price

Beryl Drugs Limited, based in Indore, was incorporated on August 24, 1993. The Company acquired the running business of M/s Flora and Fauna Remedies Limited on December 15, 1993. The Shares of Company were listed on M.P. Stock Exchange, Bombay Stock Exchange and Ahmedabad Stock Exchange.

The Company thereafter has been engaged in the manufacture, sale, and export of branded, generic pharmaceutical formulations in India and internationally. It offers I.V.fluids, and a range of small and large volume injectables. It provides a range of eye/ear drops, veterinary products, and injections. It sells products through sales and distribution network. In addition, it offers research and development, as well as contract manufacturing services. Beryl Drugs Ltd. is based in Indore, India.

Beryl emerged into a global network of pharmaceutical manufacturing, research and development, contract manufacturing services and veterinary products. It owns brands like BERI-CEF injection, F-Neuron, Amplicillin INJ, P-Mol, Biprox, B-Flox and many more.

The manufacturing facilities of the Company are in compliance with WHO GMP specifications. The Company is in tune with the current manufacturing trends in healthcare industry. The Company is an ISO 9001:2000 certified for quality management, which acknowledges quality as the first and the foremost important aspect into the business of healthcare products.

Parent organization Indian Private
NSE symbol [-]
Founded 1993
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Beryl Drugs Ltd?

Answer Field

Beryl Drugs Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 25.08 as on Sep 02 2025 03:29 PM.

What is the Market Cap of Beryl Drugs Ltd Share?

Answer Field

The market cap of Beryl Drugs Ltd for NSE ₹ 0.00 & for BSE ₹ 12.70 as on Sep 02 2025 03:29 PM.

What is the 52 Week High and Low of Beryl Drugs Ltd?

Answer Field

The 52 Week High and Low of Beryl Drugs Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 46.00 and ₹ 17.35.

What is 1 year return for Beryl Drugs Ltd?

Answer Field

The 1 year returns on the stock has been -15.14%.

What is the P/E Ratio of Beryl Drugs Ltd Share?

Answer Field

As on Sep 02 2025 03:29 PM the price-to-earnings (PE) ratio for Beryl Drugs Ltd share is 57.61.

What is the PB ratio of Beryl Drugs Ltd Share?

Answer Field

As on Sep 02 2025 03:29 PM, the price-to-book (PB) ratio for Beryl Drugs Ltd share is 18.69.

How to Buy Beryl Drugs Ltd Share?

Answer Field

You can trade in Beryl Drugs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Beryl Drugs Ltd Share on Bajaj Broking App?

Answer Field

To buy Beryl Drugs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Beryl Drugs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-image

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91